119 related articles for article (PubMed ID: 38551812)
1. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Gulla A; Morelli E; Johnstone M; Turi M; Samur MK; Botta C; Cifric S; Folino P; Vinaixa D; Barello F; Clericuzio C; Favasuli VK; Maisano D; Talluri S; Prabhala R; Bianchi G; Fulciniti M; Wen K; Kurata K; Liu J; Penailillo J; Bragoni A; Sapino A; Richardson PG; Chauhan D; Carrasco RD; Hideshima T; Munshi NC; Anderson KC
Blood; 2024 Jun; 143(25):2612-2626. PubMed ID: 38551812
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma.
Zhao L; Shen Z; Kroemer G; Kepp O
Oncoimmunology; 2024; 13(1):2360275. PubMed ID: 38812570
[TBL] [Abstract][Full Text] [Related]
3. Lack of GABARAP-Type Proteins Is Accompanied by Altered Golgi Morphology and Surfaceome Composition.
Sanwald JL; Dobner J; Simons IM; Poschmann G; Stühler K; Üffing A; Hoffmann S; Willbold D
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374830
[TBL] [Abstract][Full Text] [Related]
4. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
5. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
Jarauta V; Jaime P; Gonzalo O; de Miguel D; Ramírez-Labrada A; Martínez-Lostao L; Anel A; Pardo J; Marzo I; Naval J
Cancer Lett; 2016 Nov; 382(1):1-10. PubMed ID: 27565383
[TBL] [Abstract][Full Text] [Related]
7. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.
Xia J; He Y; Meng B; Chen S; Zhang J; Wu X; Zhu Y; Shen Y; Feng X; Guan Y; Kuang C; Guo J; Lei Q; Wu Y; An G; Li G; Qiu L; Zhan F; Zhou W
Mol Oncol; 2020 Apr; 14(4):763-778. PubMed ID: 31955515
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A; Morelli E; Samur MK; Botta C; Hideshima T; Bianchi G; Fulciniti M; Malvestiti S; Prabhala RH; Talluri S; Wen K; Tai YT; Richardson PG; Chauhan D; Sewastianik T; Carrasco RD; Munshi NC; Anderson KC
Blood Cancer Discov; 2021 Sep; 2(5):468-483. PubMed ID: 34568832
[TBL] [Abstract][Full Text] [Related]
9. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.
Gedik ME; Saatci O; Oberholtzer N; Uner M; Akbulut Caliskan O; Cetin M; Aras M; Ibis K; Caliskan B; Banoglu E; Wiemann S; Üner A; Aksoy S; Mehrotra S; Sahin O
Cancer Res; 2024 May; 84(9):1475-1490. PubMed ID: 38319231
[TBL] [Abstract][Full Text] [Related]
10. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
11. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
Chen S; Zhang Y; Zhou L; Leng Y; Lin H; Kmieciak M; Pei XY; Jones R; Orlowski RZ; Dai Y; Grant S
Blood; 2014 Oct; 124(17):2687-97. PubMed ID: 25208888
[TBL] [Abstract][Full Text] [Related]
12. Arginylated Calreticulin Increases Apoptotic Response Induced by Bortezomib in Glioma Cells.
Comba A; Bonnet LV; Goitea VE; Hallak ME; Galiano MR
Mol Neurobiol; 2019 Mar; 56(3):1653-1664. PubMed ID: 29916141
[TBL] [Abstract][Full Text] [Related]
13. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
14. Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death.
Kopecka J; Godel M; Dei S; Giampietro R; Belisario DC; Akman M; Contino M; Teodori E; Riganti C
Cells; 2020 Apr; 9(4):. PubMed ID: 32331368
[TBL] [Abstract][Full Text] [Related]
15. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Garg AD; Elsen S; Krysko DV; Vandenabeele P; de Witte P; Agostinis P
Oncotarget; 2015 Sep; 6(29):26841-60. PubMed ID: 26314964
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
17. Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner.
Yang PM; Hsieh YY; Du JL; Yen SC; Hung CF
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326356
[TBL] [Abstract][Full Text] [Related]
18. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
19. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
[TBL] [Abstract][Full Text] [Related]
20. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
